IRA & Medicare drug price negotiation
How the Biosimilars Access and Affordability Act Redefines IRA Delays
The Center for BiosimilarsTopic alignment 92
Juliana Reed, MS, of the Biosimilars Forum explains how a proposed bill would define "high likelihood" and delay Medicare negotiation for biologics.
Filed under
- IRA & Medicare drug price negotiationmatch 92
- Biosimilarsmatch 88
CMS Issues Final Rule on the Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program
AMCP (Academy of Managed Care Pharmacy)Topic alignment 95
CMS finalizes rule to codify Medicare Drug Price Negotiation Program
AHATopic alignment 95
Most-Favored-Nation Drug Pricing Framework: How Manufacturer Agreements Affect Medicaid Best Price, Contracts, and Compliance
Frier LevittTopic alignment 90
Medicare Part D Premiums and Cost Sharing in 2027
KFFTopic alignment 88